Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
myeloid fold » myeloid cell (Expand Search)
Showing 41 - 60 results of 121 for search '(( myeloid fold decrease ) OR ( euploid small decrease ))', query time: 0.73s Refine Results
  1. 41
  2. 42
  3. 43
  4. 44

    IFNγ from ASFV-specific CD4+CD8+ T cells induces TNF-production by myeloid cells. by Laia Bosch-Camós (14093985)

    Published 2022
    “…The fold decrease was calculated by dividing percentages of TNF-producing cells without IFNγ blockage by percentages of TNF-producing cells with IFNγ blockage. …”
  5. 45

    Tun increases mitochondrial fission, inflammatory cell infiltration, and decreased ER-mitochondria interaction in neonatal rat lungs. by Kirkwood A. Pritchard Jr. (13449794)

    Published 2022
    “…The decreased expressions of GRP75 (0.5±0.2-fold, p = 0.006767, n = 5) and acyl-CoA synthetase long-chain family member 4 (ASCL4; 0.3±0.1-fold, p<0.001, n = 5) indicate a decreased interaction between ER and mitochondria by Tun. …”
  6. 46

    DataSheet_1_Autolysosomal activation combined with lysosomal destabilization efficiently targets myeloid leukemia cells for cell death.doc by Harshit Shah (9375656)

    Published 2023
    “…</p>Results<p>Our analyses demonstrated several-fold higher constitutive autolysosomal activity in ML cells as compared to human CD34<sup>+</sup> hematopoietic cells. …”
  7. 47

    DataSheet1_Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models.docx by Zhiheng Yu (2433805)

    Published 2022
    “…The predicted results suggest that 1) strong, moderate, and mild CYP3A4 inhibitors (which have some overlap with CYP2C9 inhibitors) may increase olverembatinib exposure by approximately 2.39-, 1.80- to 2.39-, and 1.08-fold, respectively; strong, and moderate CYP3A4 inducers may decrease olverembatinib exposure by approximately 0.29-, and 0.35- to 0.56-fold, respectively 2); olverembatinib, as a “perpetrator,” would have no or limited impact on CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4 enzyme activity 3); systemic exposure of olverembatinib in liver function injury with Child-Pugh A, B, C may increase by 1.22-, 1.79-, and 2.13-fold, respectively. …”
  8. 48
  9. 49
  10. 50

    DataSheet_1_Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models.pdf by Meike Kaehler (4561306)

    Published 2023
    “…(Gln61Lys) variant provided a strong benefit for CML cells under TKI exposure visible by increased cell number (6.2-fold, p < 0.001) and decreased apoptosis (-25%, p < 0.001), proving the functionality of our approach. …”
  11. 51

    Table_1_Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models.xlsx by Meike Kaehler (4561306)

    Published 2023
    “…(Gln61Lys) variant provided a strong benefit for CML cells under TKI exposure visible by increased cell number (6.2-fold, p < 0.001) and decreased apoptosis (-25%, p < 0.001), proving the functionality of our approach. …”
  12. 52
  13. 53
  14. 54
  15. 55
  16. 56
  17. 57
  18. 58
  19. 59
  20. 60